Navigation Links
Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
Date:9/16/2011

CAPE TOWN, South Africa, Sept. 16, 2011 /PRNewswire/ -- Vantage Health (OTC:BB – ticker symbol VNTH), (the "Company") announces that the Tanzania Food and Drugs Authority has today issued the Company's Tanzanian subsidiary, Vantage Health Tanzania Limited ("VHTL") with all necessary licensing, permitting and registration certificates, all of which became effective in August 2011, and which will further allow VHTL to expand its business in the healthcare field in Tanzania, including both pharmaceutical wholesale and pharmaceutical retail. In addition, VHTL was officially informed today by the Tanzanian Ministry of Health and Social Welfare that VHTL's application for the evaluation of its HIV Screening Test Kits has been accepted by Tanzania's Private Health Laboratories Board ("PHLB"). Under Tanzanian law, the Test Kits must undergo an evaluation process by PHLB before being given permission to import, market and sell the devices locally.

Dr. Lisa Ramakrishnan, President and CEO of Vantage Health, said: "We have been very fortunate that the Tanzanian authorities have been so supportive of, and responsive to our VHTL subsidiary's applications. Because of the rigorous government screening protocols in place in Tanzania, license, registration and evaluation applications can take a great deal of time to be processed by the various government departments concerned. We are constantly impressed with the level of professionalism these departments have shown as we have had to navigate our way through the process. In practical terms, the finalizing of this stage of development of our Tanzanian subsidiary should allow for VHTL the broadest possible spread of commercial opportunity in the Tanzanian healthcare space. In terms of our imported Test Kits being evaluated, and given the fact it is a device as opposed to a medicine, we expect a fairly quick review process, and look forward to being able to distribute our Test Kits in Tanzania as soon as possible. We a
'/>"/>

SOURCE Vantage Health
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
6. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
7. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
8. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
9. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
10. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
11. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Verinata Health, Inc., a privately-held company dedicated to maternal ... corporate headquarters and laboratory operations to 800 Saginaw Drive, ... a much larger and state-of-the art facility is a ... growth and expansion expected with the launch of our ...
... PITTSBURGH, Dec. 7, 2011 HealthpointCapital, LLC ("HealthpointCapital") ... Inc. ("Blue Belt" or "Company"). Blue Belt is ... for use initially in orthopedic procedures and then ... ("ENT"). Terms of the transaction were not disclosed. ...
Cached Medicine Technology:Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations 2HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO 2
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... estrogen therapy does not decrease, but may increase, the ... studies have reported an association between postmenopausal estrogen use ... of estrogen or estrogen plus progestin in women aged ... dementia. In the estrogen-only trial, researchers found 47 participants ...
... the body. Parkinson's patients are particularly at risk for ... a drug commonly used to treat the disease, produces ... patients with Parkinson’s disease who have high levels of ... worse cognitive functioning than other patients who have normal ...
... about 40 milligrams of vitamin C daily as new ... may protect against rheumatoid arthritis. ,Researchers studied 23,000 ... 74. Participants' diets were assessed by using seven-day-food-intake diaries.It ... or more joints for at least one month and ...
... symptoms of rheumatoid arthritis as well as keep cardiovascular ... have an anti-inflammatory effect and are well-known for reducing ... puts sufferers at an increased risk of cardiovascular disease. ... day of atorvastatin or a placebo in addition to ...
... testicles and cause prostate cancer cells to grow. Lowering ... grow more slowly. However, hormone therapy will not cure ... such as surgery or radiation are not good options. ... cancer significantly increases the risk of fractures.For the study ...
... be risking bone loss say researchers. Investigators tested post-menopausal women ... likely to have lower scores on heel and hip tests ... ,More than 6,000 women participated in the study.The loss ... both the heel bone and the hip. Those numbers held ...
Cached Medicine News:
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
... been shown to produce the highest contact ... fixed bearing component. This combination of high ... loading minimizes the risk of polyethylene deterioration ... symmetrical component design streamlines inventory requirements without ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
Medicine Products: